Sign In
Buy MEIP
$3.07
+0 (+0%)
At Close: Dec 09, 2025
SAN DIEGO and TOKYO, June 7, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa
MEI Pharma to Host Investor and Analyst Video Webcast Event Following 2021 ASCO Annual Meeting
08:00am, Friday, 04'th Jun 2021
SAN DIEGO, June 4, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced it will host an investor a
MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021
05:00pm, Wednesday, 19'th May 2021
SAN DIEGO and TOKYO, May 19, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa
SAN DIEGO and TOKYO, May 12, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa
MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights
04:05pm, Thursday, 06'th May 2021
SAN DIEGO, May 6, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended
SAN DIEGO, April 13, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, and Kyowa Kirin Co., Ltd. (TSE:
SAN DIEGO, April 10, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data demonstr
MEI Pharma to present at the 20th Annual Needham Virtual Healthcare Conference
08:00am, Monday, 05'th Apr 2021
SAN DIEGO, April 5, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the 2
SAN DIEGO, March 10, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the abstract, Voruc
5 Stocks to Buy Now Trading Under $10 With Mammoth Upside Potential
06:15am, Saturday, 06'th Feb 2021
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Tops Revenue Estimates
06:08pm, Thursday, 04'th Feb 2021
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -46.67% and 340.09%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
MEI Pharma: Give It Another Chance
12:36pm, Saturday, 26'th Dec 2020
MEIP's pracinostat is a disaster; but zandelisib has always been its core asset. If all goes well, zandelisib may be in the market for r/r FL by 2021.
MEI Pharma, Inc. (MEIP) CEO Dan Gold on Q4 2020 Results - Earnings Call Transcript
10:40pm, Wednesday, 09'th Sep 2020
MEI Pharma, Inc. (NASDAQ:MEIP) Q4 2020 Earnings Conference Call September 9, 2020 5:00 P.M.
NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stoc
LOS ANGELES, CA / ACCESSWIRE / August 19, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against MEI Pharma, Inc.
